ME 401

Drug Profile

ME 401

Alternative Names: Kinase program - MEI Pharma; ME-401; PWT-143

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pathway Therapeutics
  • Developer MEI Pharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies

Most Recent Events

  • 08 Nov 2017 MEI Pharma plans a clinical trial for Diffuse large B-cell lymphoma (Combination therapy) in the fourth quarter of 2017
  • 31 May 2017 Safety data from a phase Ib trial in Chronic lymphocytic leukaemia and Follicular lymphoma released by MEI Pharma
  • 24 Feb 2017 MEI Pharma completes a phase I trial in Haematological malignancies in the UK (NCT02521389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top